Graham Capital Management’s Haemonetics HAE Stock Holding History

Graham Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208K	Sell	2,770 -2,921	-51%	-$188K	﹤0.01%	1029
2026 Q1	$321K	Buy	+5,691	New	+$371K	0.01%	795
2025 Q4	–	Sell	-5,116	Closed	-$249K	–	1373
2025 Q3	$249K	Sell	5,116 -1,300	-20%	-$80.5K	﹤0.01%	949
2025 Q2	$479K	Buy	+6,416	New	+$425K	0.01%	843
2024 Q2	–	Sell	-6,986	Closed	-$596K	–	1164
2024 Q1	$596K	Sell	6,986 -5,673	-45%	-$445K	0.01%	576
2023 Q4	$1.08M	Buy	+12,659	New	+$1.09M	0.02%	374
2023 Q3	–	Sell	-5,662	Closed	-$482K	–	1128
2023 Q2	$482K	Sell	5,662 -9,036	-61%	-$764K	0.01%	565
2023 Q1	$1.22M	Sell	14,698 -9,474	-39%	-$767K	0.04%	439
2022 Q4	$1.9M	Buy	24,172 +10,214	+73%	+$821K	0.06%	296
2022 Q3	$1.03M	Buy	+13,958	New	+$1M	0.04%	471

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's HAE Position: Q2 2026 in Review

Graham Capital Management reduced its Haemonetics (HAE) stake by 51% in Q2 2026, selling an estimated $188K and leaving 2,770 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Graham Capital Management first reported a position in HAE in Q3 2022 and has held it in 10 quarters since. The position peaked at $1.9M in Q4 2022. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Graham Capital Management held 2,770 shares of Haemonetics worth $208K as of Q2 2026.
Graham Capital Management sold 2,921 Haemonetics shares in Q2 2026, an estimated $188K.
Haemonetics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1029 holding.
Graham Capital Management first reported a position in Haemonetics in Q3 2022 and has held it in 10 quarters since.
Graham Capital Management's Haemonetics position peaked at $1.9M in Q4 2022.
330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.